An observational study in Varicose Veins of Lower Limb, sponsored by Russian Phlebological Association. Recruiting at 1 site in Russia. Open to participants aged 10 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Russian Phlebological Association · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A prospective cohort study of patients with primary varicose veins to assess the morbidity, risk factors and development of chronic lower limb vein disease.
Multicenter prospective cohort observational study based on a termless epidemiological registry.
Periodic inspection and collection of data from the subjects is carried out annually, in the last quarter of the current year.
Patient data is recorded in a promising digital database and is constantly updated.
226 studies on the registry are indexed under Varicose Veins; 30 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 159 across 62 observational studies indexed under Varicose Veins.
Browse Varicose Veins studies →Russian Phlebological Association is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
The main cohort is formed from those who do not have CVD, who are affected by different factors that we register (various physical activities, the presence or absence of pregnancy, etc.).
An additional cohort is formed from those who have CVD at the time of inclusion.
The goal is to track the natural evolution (progression) of the disease, to evaluate the incidence and risk factors of complications.
An extremely important criterion for the formation of the study population is the possibility to control the lower legs veins of observed individuals by a qualified vascular specialist. To date, a qualitative assessment of veins according to the CEAP classification is a weak point in longitudinal epidemiological studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals who do not have signs of chronic venous diseases of lower legs according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
Individuals who have signs of chronic venous diseases of lower legs according to CEAP classification (telangiectases, varicose veins, venous edema, skin hyperpigmentation, lipodermatosclerosis, venous ulcer).
Incidence of Chronic Venous Disease
Number of Participants with the first identified signs of chronic venous disease according to CEAP classification (telangiectasia, varicose veins, edema)
Time frame: 1 year
Natural Course of Chronic Venous Disease
Progression of CVD will be measured as a change in clinical class of CVD according to CEAP classification in every individual affected by CVD
Time frame: 1 year
Incidence of chronic venous insufficiency
Number of Participants with the first identified sign of chronic venous insufficiency (venous edema, venous eczema, hyperpigmentation of the skin, lipodermatosclerosis, venous ulcer)
Time frame: 1 year
Incidence of superficial vein thrombosis
Number of Participants with the first identified sign of superficial vein thrombosis
Time frame: 1 year
Plan to share: No
Started Aug 2020 (actual). Primary completion is estimated for Sep 2050, 360 months after the start.
Of 30 observational studies under Varicose Veins, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 360 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Russian Phlebological Association